ImmunoCellular Therapeutics (IMUC) Misses Q4 EPS by 16c

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Abivax reports Phase 3 maintenance trial results for obefazimod
• Palantir surges 4% on Nvidia sovereign AI pact as software beats semis